Ladenburg analyst Matthew Kaplan downgraded Reata Pharmaceuticals (RETA) to Neutral from Buy with a price target of $172.50, up from $122, after Biogen (BIIB) agreed to acquire Reata for $172.50 per share in cash. The firm, which is “impressed with the terms of the transaction” and believe they represent “a strong deal for both parties,” views Reata as a strong strategic fit for Biogen.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RETA:
- Reata downgraded to Market Perform from Outperform at SVB Securities
- Reata Pharmaceuticals downgraded to Hold from Buy at Jefferies
- Reata Pharmaceuticals downgraded to Neutral from Buy at Guggenheim
- Reata Pharmaceuticals downgraded to Neutral from Overweight at Cantor Fitzgerald
- Reata Pharmaceuticals downgraded to Hold from Buy at Stifel
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue